Guyasuta Investment Advisors Inc. Has $23.29 Million Holdings in Thermo Fisher Scientific Inc. (TMO)

Guyasuta Investment Advisors Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 123,100 shares of the medical research company’s stock after selling 1,102 shares during the period. Thermo Fisher Scientific accounts for 2.8% of Guyasuta Investment Advisors Inc.’s portfolio, making the stock its 12th largest position. Guyasuta Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $23,291,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Amalgamated Bank grew its holdings in shares of Thermo Fisher Scientific by 57.0% in the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after buying an additional 16,308 shares during the period. Mutual of America Capital Management LLC lifted its position in Thermo Fisher Scientific by 2.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after acquiring an additional 977 shares in the last quarter. Mitchell Capital Management Co. lifted its position in Thermo Fisher Scientific by 40.3% in the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after acquiring an additional 12,910 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Thermo Fisher Scientific by 0.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after acquiring an additional 5,213 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $1,451,000. 86.16% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. Barclays reaffirmed an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Leerink Swann reaffirmed an “outperform” rating and issued a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Finally, Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $205.21.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up $1.53 on Tuesday, reaching $189.49. 1,423,700 shares of the company were exchanged, compared to its average volume of 1,564,405. Thermo Fisher Scientific Inc. has a twelve month low of $139.88 and a twelve month high of $201.20. The firm has a market cap of $75,371.09, a price-to-earnings ratio of 20.66, a P/E/G ratio of 1.72 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the prior year, the business posted $2.03 EPS. The business’s revenue was up 13.9% compared to the same quarter last year. analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is presently 10.19%.

In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/12/guyasuta-investment-advisors-inc-has-23-29-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply